Advertisement
Editorial Comment| Volume 45, ISSUE 7, P1103-1106, May 2009

Download started.

Ok

Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS)

Published:March 16, 2009DOI:https://doi.org/10.1016/j.ejca.2009.02.009
Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS)
Previous ArticleBeing NICE is not the problem!
Next ArticleEndoscopic microwave coagulation therapy for early recurrent T1 nasopharyngeal carcinoma
      Mutations of the KIT gene are the molecular hallmark of most GISTs, and were first reported more than 10 years ago.
      • Hirota S.
      • Isozaki K.
      • Moriyama Y.
      • et al.
      Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
      Science. 1998; 279: 577-580
      Since then, GIST has become a tumour model for targeted treatment of solid tumours, imatinib becoming the standard first line treatment of these tumours in the advanced phase.
      • Verweij J.
      • Casali P.G.
      • Zalcberg J.
      • et al.
      Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
      Lancet. 2004; 364: 1127-1134
      , 
      • Blay J.Y.
      • Bonvalot S.
      • Casali P.
      • et al.
      GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO.
      Ann Oncol. 2005; 16: 566-578
      , 
      • Demetri G.D.
      • Benjamin R.S.
      • Blanke C.D.
      • et al.
      NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)–update of the NCCN clinical practice guidelines.
      J Natl Compr Cancer Netw. 2007; 5: S1-29
      , 
      • Casali P.G.
      • Jost L.
      • Reichardt P.
      • Schlemmer M.
      • Blay J.Y.
      ESMO Guidelines Working Group
      Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.
      Ann Oncol. 2008; 19: ii35-38
      Following the introduction of imatinib, the median survival of advanced GIST increased from 18 months to 60 months in the most recent update of the B2222 trial, i.e. the trial with the longest follow-up so far.
      • Blanke C.D.
      • Demetri G.D.
      • von Mehren M.
      • et al.
      Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
      J Clin Oncol. 2008; 26: 620-625
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Hirota S.
        • Isozaki K.
        • Moriyama Y.
        • et al.
        Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
        Science. 1998; 279: 577-580
        View in Article
        • Verweij J.
        • Casali P.G.
        • Zalcberg J.
        • et al.
        Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
        Lancet. 2004; 364: 1127-1134
        View in Article
        • Blay J.Y.
        • Bonvalot S.
        • Casali P.
        • et al.
        GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO.
        Ann Oncol. 2005; 16: 566-578
        View in Article
        • Demetri G.D.
        • Benjamin R.S.
        • Blanke C.D.
        • et al.
        NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)–update of the NCCN clinical practice guidelines.
        J Natl Compr Cancer Netw. 2007; 5: S1-29
        View in Article
        • Casali P.G.
        • Jost L.
        • Reichardt P.
        • Schlemmer M.
        • Blay J.Y.
        • ESMO Guidelines Working Group
        Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.
        Ann Oncol. 2008; 19: ii35-38
        View in Article
        • Blanke C.D.
        • Demetri G.D.
        • von Mehren M.
        • et al.
        Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
        J Clin Oncol. 2008; 26: 620-625
        View in Article
        • Dematteo R.P.
        • Owzar K.
        • Maki R.
        • et al.
        Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001.
        J Clin Oncol (Meeting Abstracts). 2007; 25: 10079
        View in Article

      8. http://www.fda.gov/cder/foi/label/2008/021588s025lbl.pdf.

        View in Article
        • Blay J.Y.
        • Le Cesne A.
        • Ray-Coquard I.
        • et al.
        Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
        J Clin Oncol. 2007; 25: 1107-1113
        View in Article
        • Le Cesne A.
        • Ray-Coquard I.
        • Bui B.
        • et al.
        Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group.
        J Clin Oncol (Meeting Abstracts). 2007; 25: 10005
        View in Article
        • Fletcher C.D.
        • Berman J.J.
        • Corless C.
        • et al.
        Diagnosis of gastrointestinal stromal tumors: a consensus approach.
        Hum Pathol. 2002; 33: 459-465
        View in Article
        • Miettinen M.
        • Lasota J.
        Gastrointestinal stromal tumors: pathology and prognosis at different sites.
        Semin Diagn Pathol. 2006; 23: 70-83
        View in Article
        • Martín J.
        • Poveda A.
        • Llombart-Bosch A.
        • et al.
        Deletions affecting codons 557–558 of the c-kit gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors. A study by the Spanish group for sarcoma research (GEIS).
        J Clin Oncol. 2005; 23: 6190-6198
        View in Article
        • Singer S.
        • Rubin B.P.
        • Lux M.L.
        • et al.
        Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.
        J Clin Oncol. 2002; 20: 3898-3905
        View in Article
        • Emile J.F.
        • Théou N.
        • Tabone S.
        • et al.
        Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors.
        Clin Gastroenterol Hepatol. 2004; 2: 597-605
        View in Article
        • Aparicio T.
        • Boige V.
        • Sabourin J.C.
        • et al.
        Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours.
        Eur J Surg Oncol. 2004; 30: 1098-1103
        View in Article
        • Debiec-Rychter M.
        • Sciot R.
        • Le Cesne A.
        • et al.
        KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
        Eur J Cancer. 2006; 42: 1093-1103
        View in Article
        • Van Glabbeke M.M.
        • Owzar K.
        • Rankin C.
        • et al.
        Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analyis based on 1,640 patients (pts).
        J Clin Oncol (Meeting Abstracts). 2007; 25: 10004
        View in Article
        • Heinrich M.C.
        • Corless C.L.
        • Duensing A.
        • et al.
        PDGFRA activating mutations in gastrointestinal stromal tumors.
        Science. 2003; 299: 708-710
        View in Article
        • Corless C.L.
        • Schroeder A.
        • Griffith D.
        • et al.
        PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
        J Clin Oncol. 2005; 23: 5357-5364
        View in Article
        • Corless C.L.
        • Fletcher J.A.
        • Heinrich M.C.
        Biology of gastrointestinal stromal tumors.
        J Clin Oncol. 2004; 22: 3813-3825
        View in Article

      Article info

      Publication history

      Published online: March 16, 2009
      Accepted: February 5, 2009
      Received: February 4, 2009

      Identification

      DOI: https://doi.org/10.1016/j.ejca.2009.02.009

      Copyright

      © 2009 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX